Shiba et al. previously reported that canagliflozin attenuates the development of HCC in melanocortin 4 receptor-deficient mice fed a Western diet, a mouse model of human HCC, with the number of liver tumors being significantly reduced by canagliflozin treatment when compared with the placebo [17]. The gene discussed is MC4R; the disease is hepatocellular carcinoma.